An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

Jarome and his team found that aging disrupts K63 polyubiquitination in two distinct areas of the brain. In the hippocampus, ...